Drug Trial Radar · NCT07043751
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.
Conditions
- Advanced Malignant Tumors
Interventions
TQB6411 injectionDrug
TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting intravenously, the antibody part of this product binds to the EGFR and c-Met on the surface of tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enrolled and transported to the lysosome through cells. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: Up to24 months
- Maximum Tolerated DoseTime frame: Up to24 months
- Phase II recommended doseTime frame: Up to24 months
- Rate and severity of adverse eventsTime frame: Up to24 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Dongguan People's Hospital
Dongguan, Guangdong, China · Not yet recruiting
ZhuJiang Hospital of Southern Medical University
Guangdong, Guangdong, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Anyang Tumor Hospital
Anyang, Henan, China · Not yet recruiting
The Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Zhongnan Hospital Of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
the Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Jining First People's Hospital
Jining, Shandong, China · Not yet recruiting
Shanghai Jiaotong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Mianyang Central Hospital
Mianyang, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.